The vaccine is widely known as a pandemic killer.
Washington— AstraZeneca’s coronavirus vaccine is considered to be an injection that can free the world from the pandemic-a cheap, easy-to-administer vaccine that protects not only the citizens of the richest countries, but also the citizens of the most vulnerable countries. .
Instead, as the introduction of other vaccines has accelerated, the collaborative vaccination work between Oxford University researchers and one of the world’s largest pharmaceutical companies has been plagued by mistakes. First, basic science is confusing. Then, it did not reach the delivery target. Now, in Europe, there is a pause in the decline of confidence, and then there are reports of rare blood clots in a few cases of vaccinations.
If the stakes are not so high, then the AstraZeneca legend may be like a soap opera, with embarrassing mistakes ruining the dazzling scientific moments of science. The Oxford University vaccine research and development team is bold, but it also makes many scientists on both sides of the Atlantic proud.
If the launch of the AstraZeneca vaccine is handled differently, it may now be more widely used, thereby alleviating a new wave of life-threatening deaths and diseases worldwide. Countries that extensively manage the disease, such as the United Kingdom, praised AstraZeneca for helping to drive the sharp decline in hospitalizations and deaths. However, public confidence in the company’s vaccine has been severely hit, slowing its acceptance and delaying the fight against the pandemic.
There is no clearer consequence than in Europe. In Europe, people are betting heavily on the dose of AstraZeneca vaccine, but only one-third of the promise has been received. Many countries are now closed again because the most contagious variant of the coronavirus first discovered in the UK spreads across the entire African continent. Hungary broke the death and case record last Friday. France imposed a new strict blockade on most of the country. Cases from Germany increased by 50% last week. Opinion polls show that the public’s willingness to accept the AstraZeneca vaccine is declining.
European Commission President Ursula von der Leyen told reporters: “Unfortunately, AstraZeneca’s production and supply are in short supply. “Of course, this slowed the vaccination campaign. “